Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen P M, Klein G, Kurilla M G, Masucci M G
Microbiology and Tumour Biology Center, Karolinska Institute, Stockholm, Sweden.
Nature. 1995 Jun 22;375(6533):685-8. doi: 10.1038/375685a0.
The Epstein-Barr virus (EBV)-encoded nuclear antigen (EBNA1) is expressed in latently EBV-infected B lymphocytes that persist for life in healthy virus carriers, and is the only viral protein regularly detected in all malignancies associated with EBV. Major histocompatibility complex (MHC) class I-restricted, EBNA1-specific cytotoxic T lymphocyte (CTL) responses have not been demonstrated. Using recombinant vaccinia viruses encoding chimaeric proteins containing an immunodominant human leukocyte antigen A11-restricted CTL epitope, amino acids 416-424 of the EBNA4 protein, inserted within the intact EBNA1, or within an EBNA1 deletion mutant devoid of the internal Gly-Ala repetitive sequence, we demonstrate that the Gly-Ala repeats generate a cis-acting inhibitory signal that interferes with antigen processing and MHC class I-restricted presentation. Insertion of the Gly-Ala repeats downstream of the 416-424 epitope inhibited CTL recognition of a chimaeric EBNA4 protein. The results highlight a previously unknown mechanism of viral escape from CTL surveillance, and support the view that the resistance of cells expressing EBNA1 to rejection mediated by CTL is a critical requirement for EBV persistence and pathogenesis.
爱泼斯坦-巴尔病毒(EBV)编码的核抗原(EBNA1)在潜伏性EBV感染的B淋巴细胞中表达,这些细胞在健康病毒携带者体内终生存在,并且是在所有与EBV相关的恶性肿瘤中均能定期检测到的唯一病毒蛋白。尚未证实主要组织相容性复合体(MHC)I类限制性、EBNA1特异性细胞毒性T淋巴细胞(CTL)反应。使用编码嵌合蛋白的重组痘苗病毒,这些嵌合蛋白包含一个免疫显性的人类白细胞抗原A11限制性CTL表位,即EBNA4蛋白的第416-424位氨基酸,插入完整的EBNA1内,或插入缺乏内部Gly-Ala重复序列的EBNA1缺失突变体内,我们证明Gly-Ala重复序列产生一个顺式作用抑制信号,干扰抗原加工和MHC I类限制性提呈。将Gly-Ala重复序列插入416-424表位下游可抑制CTL对嵌合EBNA4蛋白的识别。这些结果突出了病毒逃避CTL监视的一种此前未知的机制,并支持这样一种观点,即表达EBNA1的细胞对CTL介导的排斥具有抗性是EBV持续存在和发病机制的关键要求。